A5086011253- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Pneumocystis jirovecii pneumonia detection and treatment
- Histone Deacetylase Inhibitors Research
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
- Hematological disorders and diagnostics
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Lymphoma Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Diabetic Foot Ulcer Assessment and Management
- Peptidase Inhibition and Analysis
- T-cell and B-cell Immunology
- Hematopoietic Stem Cell Transplantation
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Cystic Fibrosis Research Advances
The University of Texas MD Anderson Cancer Center
2013-2024
Sidney Kimmel Comprehensive Cancer Center
2017-2024
Johns Hopkins University
2016-2024
Moffitt Cancer Center
2018-2022
TP53 mutation (TP53mut ) confers an adverse prognosis in acute myeloid leukemia (AML). Venetoclax with hypomethylating agents is a current standard for older patients; however, recent reports suggest that TP53mut resistance to venetoclax. The authors investigated the outcomes of patients AML who were treated 10-day decitabine and venetoclax (DEC10-VEN) (ClinicalTrials.gov identifier NCT03404193).Patients newly diagnosed received 20 mg/m2 10 days every 4 6 weeks induction, followed by 5 after...
Summary Programmed cell death protein 1 (PD‐1) and PD‐ligand (PD‐L1) expression is upregulated in cluster of differentiation 34 (CD34) + bone marrow cells from patients with myelodysplastic syndromes (MDS). Hypomethylating agent (HMA) treatment results further increased these immune checkpoints. We hypothesised that combining an anti‐PD‐1 antibody HMAs may have efficacy MDS. To test this concept, we designed a phase II trial the combination azacitidine pembrolizumab two cohorts. In 17...
Abstract Ag activation of the BCR may play a role in pathogenesis human follicular lymphoma (FL) and other B cell malignancies. However, nature Ag(s) recognized by tumor BCRs has not been well studied. In this study, we used unbiased approaches to demonstrate that 42 (19.35%) 217 tested FL Igs vimentin as shared autoantigen. The epitope was localized N-terminal region for all vimentin-reactive Igs. We confirmed specific binding using recombinant performing competitive inhibition studies....
A defining hallmark of primary and metastatic cancers is the migration invasion malignant cells. These invasive properties involve altered dynamics cytoskeleton one its major structural components β-actin. Here we identify AIM1 (absent in melanoma 1) as an actin-binding protein that suppresses pro-invasive benign prostate epithelium. Depletion epithelial cells increases cytoskeletal remodeling, intracellular traction forces, cell invasion, anchorage-independent growth. In addition, decreased...
The occurrence of somatic mutations in patients with no evidence hematological disorders is called clonal hematopoiesis (CH). CH, whose subtypes include CH indeterminate potential and cytopenia undetermined significance, has been associated both hematologic cancers systemic comorbidities. However, CH's effect on patients, especially those concomitant malignancies, not fully understood.
Activating mutations in RAS have been reported about 10-15% of patients with AML; previous studies not identified a prognostic significance. However, emerged as potential resistance mechanism to treatment inhibitors FLT3, IDH, and BCL2. We aimed determine the characteristics outcomes RAS-mutated (RAS-mut) AML across therapy subsets 1410 newly diagnosed (ND AML). RAS-mut was observed 273 (20%) patients. Overall, had an estimated 3-year survival rate 38% vs. 28% those wild type (RAS-wt), p =...
SUMMARY While nucleoside DNA methyltransferase inhibitors (DNMTi) such as decitabine and azacitidine are effective in treating myelodysplatic syndrome (MDS)/leukemia, they have had limited utility for the majority of other cancers. Through a chemical library screen, we identified that triptolide, diterpenoid epoxide from Tripterygium wilfordii , or analogs significantly augmented epigenetic anti-cancer effects vitro vivo . These were attributable to inhibition DCTPP1-mediated cleavage...
Purpose: mAbs such as anti-CD20 rituximab are proven therapies in B-cell malignancies, yet many patients develop resistance. Novel against alternative targets needed to circumvent resistance mechanisms. We sought generate human B-cell-activating factor receptor (BAFF-R/TNFRSF13C), which has not been targeted successfully for cancer therapy.Experimental Design: were generated BAFF-R, expressed a natively folded cell surface immunogen on mouse fibroblast cells. Chimeric BAFF-R developed and...
Hearing loss is associated with an accelerated decline in social, cognitive, and physical functioning among older adults. However, little known about its impact barriers to hearing health care any ethnic minorities. The aim of this study was explore experiences related Korean Americans (KAs). We conducted four focus groups 19 KAs communication partners. Qualitative content analysis revealed themes: (a) loss, (b) self-perception (c) coping strategies for (d) (price, language, lack...
AML presenting with hyperleukocytosis is associated poor outcomes. We aim to understand the factors early mortality and overall survival (OS) help guide management improve mortality.
Newly diagnosed acute myeloid leukemia is often deemed a medical emergency, requiring urgent treatment. This in contradiction with the need for accurate cytogenetic and molecular data, which not immediately available, to select optimal therapy. We hypothesized that cytoreduction hydroxyurea or cytarabine would enable disease control provide bridge clinical trial enrollment. analyzed three prospective frontline trials allowed use of before treatment initiation. Among 274 patients median age...
251 Background: Combination chemotherapy with nab-paclitaxel/gemcitabine is a standard of care option in metastatic pancreatic cancer management increasing use due to an improvement median overall survival 1.8 months compared gemcitabine alone. It also used practice the second and third-line settings for patients that have progressed on fluorouracil based regimens. As utility this combination has grown, dose intensity (DI) relation outcome important measure real world application. Methods:...
9100 Background: V600E and V600K mutations are the most common BRAF in melanoma. We previously showed that non-V600 account for 12% of all Limited clinical data available mutant melanomas. To better understand melanoma, characteristics tumor outcomes were investigated. Methods: Clinical pathologic collected retrospectively patients (pts) with melanoma who had multi-gene mutation analysis (next-gene sequencing) at MD Anderson Cancer Center. Fisher's exact test was used comparisons. Results:...
7025 Background: Patients (pts) with AML frequently encounter life-threatening complications requiring transfer to an intensive care unit (ICU). Methods: Retrospective analysis of 145 adults ICU admission at our tertiary cancer center 2018-19. Use life-sustaining therapies (LSTs) and overall survival (OS) were reported using descriptive statistics. Logistic regression was used identify risk factors for in-hospital death. Results: Median age 64 yrs (range 18-86). 47% pts had ECOG status ≥ 2 a...